Initiating PCSK9 mAb after ACS: When and how to start?10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD (Leiden, The Netherlands) and Prof. Pasquale Perrone-Filardi, MD, PhD (Naples, Italy)
Video navigation menu
- The AT-TARGET-IT study 0:31
- Why start early? 3:32
- Prolonged benefit of lower LDL-c 6:13
- Adherence and persistence 7:17
In ACS patients who need additional lipid-lowering therapy, do you initiate a PCSK9 inhibitor during their hospital stay?
- Yes, always
- Sometimes, it varies per patient
- No, I wait until follow-up
- No, I prescribe another agent
This video is part of a serie of expert discussions titled "Innovating science and practice - Broadening the understanding of PCSK9 mAb".
Prof. J. Wouter Jukema, MD, PhD is Professor of Cardiology at the Leiden University Medical Center in Leiden, The Netherlands.
Prof. Pasquale Perrone-Filardi, MD, PhD - Department of Clinical Medicine, Cardiovascular and Immunology Sciences, Federico II University, Naples, Italy.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Sanofi.